Circadian-dependent effect of melatonin on dopaminergic D 2 antagonist-induced hypokinesia and agonist-induced stereotypies in rats

Pharmacology Biochemistry and Behavior

Volumn 78, Issue 4, 2004, Pages 727-733

  Sumaya, I C ^a,b   Byers, D M ^a   Irwin, L N ^a   Del Val, S ^a   Moss, D E ^a  

^a UNIVERSITY OF TEXAS AT EL PASO   (United States)

^b 9001 Stockdale Highway 93311 1099 ^*  (United States)

Author keywords

Catalepsy; Extrapyramidal system; Locomotor behavior; Pineal; Striatum

Indexed keywords

APOMORPHINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FLUPHENAZINE; MELATONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG EFFECT; HORMONE ACTION; HYPOKINESIA; LIGHT DARK CYCLE; LOCOMOTION; MALE; NIGHT SLEEP; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; STEREOTYPY;

ANIMALS; APOMORPHINE; CIRCADIAN RHYTHM; DARKNESS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; FLUPHENAZINE; HYPOKINESIA; LIGHT; MALE; MELATONIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; STEREOTYPED BEHAVIOR;

EID: 3843121080     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2004.05.014     Document Type: Article

References (45)

1. Benloucif S., Dubocovich M.L. Melatonin and light induce phase shifts of circadian activity rhythms in the C3H/HeN mouse. J. Biol. Rhythms. 11(2):1996;113-125
2. Castillo-Romero J.L., Vives-Montero F., Acuna-Castroviejo D. Paradoxical effects of melatonin on spontaneous neuronal activity in the striatum of sham-operated and pinealectomized rats. J. Pineal Res. 12:1992;149-154
3. Castillo-Romero J.L., Acuna-Castroviejo D., Escames G., Vives F. Age-related changes of neuronal responsiveness to melatonin in the striatum of sham-operated and pinealectomized rats. J. Pineal Res. 19(2):1995;79-86
4. Chen J.F., Weiss B. Irreversible blockade of D2 dopamine receptors by fluphenazine N-mustard increases glutamic acid decarboxylase mRNA in rat striatum. Neurosci. Lett. 150(2):1993;215-218
5. Cho A.K., Melega W.P., Kuczenski R., Segal D.S., Schmitz A. Caudate-putamen and stereotypy response profiles after intravenous and subcutaneous amphetamine. Synapse. 31:1991;125-133
6. Chuang J.-I., Lin M.-T. Pharmacological effects of melatonin treatment on both locomotor activity and brain serotonin release in rats. J. Pineal Res. 17:1994;11-16
7. Cohen B.M., Tsuneizumi T., Baldessarini R.J., Campbell A., Babb S.M. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology (Berl.). 108(3):1992;338-344
8. Dubocovich M.L. Melatonin is a potent modulator of dopamine release in the retina. Nature. 306(5945):1983;782-784
9. Dubocovich M.L., Benloucif S., Masana M. Melatonin receptors in the mammalian suprachiasmatic nucleus. Behav. Brain Res. 73:1996;141-147
10. Escames G., Castroviejo D.A., Vives F. Melatonin-dopamine interaction in the striatal projection area of sensorimotor cortex in the rat. NeuroReport. 7(2):1996;597-600
11. Fernandez H.H., Freeman J.H. Classification and treatment of tardive syndromes. Neurology. 9(1):2003;16-27
12. Gancher S. Pharmacokinetics of apomorphine in Parkinson's disease. J. Neural Transm., Suppl. 45:1995;137-141
13. Gibbs F.P., Vriend J. The half-life of melatonin elimination from rat plasma. Endocrinology. 109(5):1981;1796-1798
14. Hamdi A. Melatonin administration increases the affinity of D2 dopamine receptors in the rat striatum. Life Sci. 63(23):1998;2115-2120
15. Hata T., Kita T. A newly designed method for removal of the pineal body, and depression of convulsions and enhancement of exploratory movements by pinealectomy in mice. Endocrinol. Jpn. 25(5):1987;407-413
16. Hernandez G., Abreu P., Alonso R., Calzadilla C.H. Determination of pineal melatonin by high-performance liquid chromatography with electrochemical detection: application for rhythm studies and tissue explants. J. Pineal Res. 8(1):1990;11-19
17. 2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am. J. Physiol., Cell Physiol. 280:2001;C110-C118
18. Jaliffa C.O., Lacoste F.F., Llomovatte D.W., Sarmiento M.I., Rosenstein R.E. Dopamine decreased melatonin content in golden hamster retina. J. Pharmacol. Exp. Ther. 293(1):2000;91-95
19. Joel D., Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to functional and compartmental organization. Neuroscience. 96(3):2000;451-474
20. Khaldy H., Leon J., Ecames G., Bikjdaouene L., Garcia J.J., Acuna-Castroviejo D. Circadian rhythms of dopamine and dihydorxyphenyl acetic acid in the mouse striatum: effects of pinealectomy and of melatonin treatment. Neuroendocrinology. 75:2002;201-208
21. Kunz D., Bes F. Exogenous melatonin in periodic limb movement disorder: an open clinical trial and a hypothesis. Sleep. 24(2):2001;183-187
22. Mittler T., Cho J., Peoples L.L., West M.O. Representation of the body in the lateral striatum of the freely moving rat: single neurons related to licking. Exp. Brain Res. 98(1):1994;163-167
23. Morgan P.J., Barrett P., Howell H.E., Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem. Int. 24(2):1994;101-146
24. Moss D.E., Manderscheid P.Z., Montgomery S.P., Norman A.B., Sanberg P.R. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci. 44:1989;1521-1525
25. Muller-Vahl K.R., Berding G., Kolbe H., Meyer G.J., Hundeshagan H., Dengler R., et al. Dopamine D2 receptor imaging in Gilles de la Tourette syndrome. Acta Neurol. Scand. 101(3):2000;165-171
26. Murakami N., Kawano T., Nakahara K., Nasu T., Shiota K. Effect of melatonin on circadian rhythm, locomotor activity and body temperature in the intact house sparrow, Japanese quail and owl. Brain Res. 889:2001;220-224
27. Naber D., Wirz-Justice A., Kafka M.S., Wehr T.A. Dopamine receptor binding in rat striatum: ultradian rhythm and its modification by chronic imipramine. Psychopharmacology (Berl.). 68(1):1980;1-5
28. Naber D., Wirz-Justice A., Kafka M.S., Tobler I., Borbely A.A. Seasonal variations in the endogenous rhythm of dopamine receptor binding in rat striatum. Biol. Psychiatry. 16(9):1981;831-835
29. Paredes D., Rada P., Bonilla E., Gonzales L.E., Parada M., Hernandez L. Melatonin acts on the nucleus accumbens to increase acetylcholine release and modify the motor activity pattern of rats. Brain Res. 850:1999;14-20
30. Poirel V.-J., Cailotto C., Strecher D., Pevet P., Masson-Pevet M., Gauer F. MT1 melatonin receptor mRNA tissular localization by PCR amplification. Neuroendocrinol. Lett. 24(1-2):2003;33-38
31. Planeta C.S., DeLucia R., Aizenstein M.L., Oliveira G.H. Daily variations in plasma concentration of fencamfamine and striatal dopamine receptors in rats. Braz. J. Biol. Res. 27(3):1994;737-741
32. Raghavendra V., Naidu P.S., Kulkarni S.K. Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvements of peripheral benzodiazepine receptors. Brain Res. 904:2001;149-152
33. Reppert S.M. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J. Biol. Rhythms. 12(6):1997;528-531
34. Shamir E., Barak Y., Shalman I., Laudon M., Zisapel N., Tarrasch R., et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch. Gen. Psychiatry. 58(11):2001;1049- 1052
35. Silvestri R., Seeman M.V., Negrete J.C., Houle S., Shammi C.M., Remington C.J., et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl.). 152(2):2000;174-180
36. Sugden D. Psychopharmacological effects of melatonin in mouse and rat. J. Pharmacol. Exp. Ther. 227:1983;587-591
37. Tamminga C.C., Gerlach J. New neuroleptics and experimental antipsychotics in schizophrenia. Meltzer H.Y. Psychopharmacology: the third generation of progress. 1987;1129-1147 Haven Press, New York
38. Tenn C.C., Niles L.P. The antidopaminergic action of S-20098 is mediated by benzodiazepine/GABA (A) receptors in the striatum. Brain Res. 756(1-2):1997;293-296
39. Tieppo C.A., Nasello A.G., Felicio L.F. Modulation of apomorphine-induced stereotyped behavior by cholecystokinin. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 21(4):1997;683-695
40. Tieppo C.A., Ferreira F.S., Sassatani A.S., Felicio L.F., Nasello A.G. Opposite modulation of apomorphine-or amphetamine-induced stereotypy by antagonists of CCK receptors. Eur. J. Pharmacol. 387:2000;189-196
41. Tosini G., Dirden J.C. Dopamine inhibits release in the mammalian retina: in vitro evidence. Neurosci. Lett. 286(2):2002;119-122
42. Viyoch J., Ohdo S., Yukawa E., Higuchi S. Dosing time-dependent tolerance of catalepsy by repetitive administration of haloperidol in mice. J. Pharmacol. Exp. Ther. 298:2001;964-969
43. Zhdanova I.V., Cantor M.L., Leclair O.U., Kartashov A.I., Wurtman R.J. Behavioral effects of melatonin treatment in non-human primates. Sleep Res. Online. 1(3):1998;114-118
44. Zisapel N., Egozi Y., Laudon M. Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Res. 246(1):1982;161-163
45. Zisapel N., Nir I., Laudon M. Circadian variations in melatonin-binding sites in discrete areas of the male brain. FEBS Lett. 232(1):1988;72-176